SAB Biotherapeutics, Inc., (SABS) Social Stream



SAB Biotherapeutics, Inc., (SABS): $0.42

0.00 (0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SABS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

SAB BIOTHERAPEUTICS INC (SABS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering SABS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-23 4 $23 $16.5 $18.625 $0.469 3871.22%
2021-12-02 4 $23 $16.5 $19.375 $0.469 4031.13%
2022-03-31 4 $23 $9 $16.375 $0.469 3391.47%
2022-04-04 4 $23 $9 $14.625 $0.469 3018.34%
2022-04-06 4 $23 $9 $14.1 $0.469 2906.4%
2022-05-15 4 $23 $7 $13.35 $0.469 2746.48%
2022-05-17 4 $23 $7 $12.85 $0.469 2639.87%
2022-08-11 4 $12.4 $3 $7.1 $0.469 1413.86%
2022-08-23 3 $9 $3 $6.062 $0.469 1192.54%
2022-11-16 2 $9 $3 $6.062 $0.469 1192.54%
2022-11-21 3 $9 $3 $5.75 $0.469 1126.01%
2023-01-18 3 $9 $3 $5.4 $0.469 1051.39%

The Trend in the Analyst Price Target


SABS's average price target has moved down $0.66 over the prior 63 days.

SABS reports an average of 483.26% for its upside potential over the past 42 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-03-31 4 23 9 16.375 3.760 335.51%
2022-04-06 4 23 9 14.100 2.650 432.08%
2022-08-23 3 9 3 6.062 0.945 541.48%
2022-11-16 2 9 3 6.062 1.050 477.33%
2022-11-21 2 9 3 5.750 1.090 427.52%

SABS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 3 0 0 0 0 3

The Trend in the Broker Recommendations


Over the past 35 weeks, SABS's average broker recommendation rating improved by 0.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SABS as an investment opportunity.

  • SABS has a higher upside potential (average analyst target price relative to current price) than 1371.33% of all US stocks.
  • In terms of how SAB BIOTHERAPEUTICS INC fares relative to all US stocks, note that its average analyst price target is higher than 169.4% of that group.
  • To contextualize these metrics, consider that out of Healthcare stocks, SAB BIOTHERAPEUTICS INC's number of analysts covering the stock is greater than 207.22% of them.
  • SABS has a lower variance in analysts' estimates than -1017.02% of stocks in the small market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to SAB BIOTHERAPEUTICS INC are GRNA, VOR, and FNCH.

Make investment decisions regarding SABS using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6561 seconds.